Hybrid and decentralized clinical trials (DCTs) are becoming more prevalent as they can better address the constraints associated with in-person visits including: mobility, proximity to research sites and the time or cost associated with attending the clinic. Although DCTs can be more convenient than in-person trials, is there a risk of relying too much on technology at the expense of person-centered communication?